Director, Clinical Operations
Christina focuses on management for rare disease and novel therapy studies. She has developed study management tools, processes and procedures that facilitate operations from study conception to study close-out. Prior to joining Aceragen, she spearheaded a COVID-19 treatment trial with the focus on rapid study take-off.
With over 18 years’ working in pharma, biotech, CROs and research centers, Christina brings a wealth of experience including management and monitoring of Phase 1 through Phase 4 pharmaceutical, biologic, device and tobacco studies. A graduate of the University of the Sciences in Philadelphia with an MBA in pharmaceutical business and multiple research certifications, she previously worked in orthopedic research.